AbbVie (NYSE: ABBV) topped revenue and earnings expectations for the fourth quarter of 2019, allowing the stock to gain over 3% in
AbbVie Inc.
-(ABBV)
Get the latest AbbVie Inc. (ABBV) stock news, earnings analysis, earnings conference calls, earnings transcripts from AlphaStreet.
AbbVie (ABBV) Q4 earnings preview: Generic competition might weigh on results
With only a few weeks left for closing the high-value acquisition of Allergan, AbbVie (NYSE: ABBV) is busy doing the groundwork for
AbbVie (NYSE: ABBV) Q3 profit dips 31% but beats estimates
AbbVie Inc. (NYSE: ABBV) reported a 31% dip in earnings for the third quarter of 2019 due to higher costs and expenses.
Will Allergan-AbbVie merger be intercepted
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing from the
AbbVie tops Q2 views; lifts FY19 earnings outlook
AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
What to expect from AbbVie Q2 earnings
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
M&A alert: AbbVie agrees to acquire Allergan for $63 billion
Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE:
Abbvie’s oncology push makes it an attractive stock
Abbvie (NYSE: ABBV) is one of the worse performing pharma stocks in the trailing 12-month period. The stock has declined almost 19%
AbbVie’s stock gains after Q1 results top expectations
AbbVie Inc. (NYSE: ABBV) surpassed market estimates on revenue and earnings for the first quarter of 2019, giving shares a lift of
Earnings preview: Merck to ride the wave of expanding oncology portfolio in Q4
The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict
AbbVie slips to loss in Q4, misses estimates
AbbVie Inc. (ABBV) slipped to a loss in the fourth quarter from a profit last year, due to the inclusion of the
Companies reporting earnings this week: Jan 22 – 25
A slew of major companies are reporting earnings this week. Healthcare giant Johnson & Johnson (JNJ) will announce fourth-quarter earnings on Tuesday
European competition threatens AbbVie’s run of top-selling Humira
US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to
AbbVie Q3 profit jumps 68%, beats estimates
AbbVie Inc. (ABBV) reported a 68% jump in earnings for the third quarter helped by sales growth from Humira, Imbruvica, and HCV.